Dengue Vaccine Market Research, Trends, Overview, and Growth Report Analysis 2024-2033

"The Business Research Company recently released a comprehensive report on the Global Dengue Vaccine Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

According to The Business Research Company's, The dengue vaccine market size has grown rapidly in recent years. It will grow from $0.57 billion in 2023 to $0.64 billion in 2024 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to growing travel and urbanization, increasing demand for effective vaccines, increasing prevalence of foreign travel exposure, increasing healthcare services, and rising mass vaccinations.

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to the increasing incidence of dengue, increasing initiatives by several organizations, increasing clinical trials, and growing emphasis on multi-strain and tetravalent vaccine formulations. Major trends in the forecast period include increasing demand for preventative vaccines, advancements in vaccine technology, development of combination vaccines, rise in research and clinical trials for new vaccine candidates, and focus on improving vaccine efficacy and safety profiles.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report

Market Drivers and Trends:

The rising number of dengue fever cases is expected to propel the growth of the dengue vaccine markets going forward. Dengue fever is a viral infection spread by Aedes aegypti mosquitoes, causing high fever, headaches, joint pain, and rashes. The rise in dengue fever cases is due to climate change, urbanization, inadequate mosquito control, and viral evolution. The dengue vaccine works by activating the immune system to identify and combat the dengue virus. It lessens infection severity and reduces the risk of severe complications, helping to decrease cases and hospitalizations. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, from 4.6 million cases reported in 2023. Therefore, the rising number of dengue fever cases is driving the growth of the dengue vaccine market.

Major companies operating in the dengue vaccine market are focused on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, to enhance protection against all four dengue virus serotypes in a single formulation. The dengue tetravalent vaccine provides immunity against all four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, received European Commission (EC) approval for QDENGA vaccine use in individuals from 4 years of age and older. It is a live-attenuated vaccine used in several dengue-endemic countries to protect against dengue fever. It uses a weakened dengue serotype two viruses as a genetic foundation for the other three serotypes. It is administered in two doses of 0.5 mL each at 0 and 3 months and targets individuals aged four years and older. A Phase 3 trial showed Qdenga has an efficacy of about 80.2% against dengue, with better results in preventing hospitalizations. Its protection lasts approximately 4.5 years, longer than many other vaccines.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Dengue Vaccine Market 2024 Key Insights:

• The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%.
• Surge In Dengue Fever Cases Fuels Growth In The Dengue Vaccine Market
• Advancements In Dengue Tetravalent Vaccines Enhance Comprehensive Protection Against All Serotypes
• Asia-Pacific was the largest region in the dengue vaccine market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=19026&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"""Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.